191 related articles for article (PubMed ID: 38183209)
1. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
2. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
3. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
4. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Moreau P; Touzeau C
Blood; 2022 Jun; 139(26):3681-3687. PubMed ID: 35404996
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
6. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
Hosny M; Verkleij CPM; van der Schans J; Frerichs KA; Mutis T; Zweegman S; van de Donk NWCJ
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640611
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
8. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
9. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
10. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
[TBL] [Abstract][Full Text] [Related]
11. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.
O'Neill C; van de Donk NWCJ
EJHaem; 2023 Aug; 4(3):811-822. PubMed ID: 37601851
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
Wang X; Zhao A; Zhu J; Niu T
Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
[TBL] [Abstract][Full Text] [Related]
13. Bispecific Antibodies for the Treatment of Multiple Myeloma.
Goldsmith SR; Streeter S; Covut F
Curr Hematol Malig Rep; 2022 Dec; 17(6):286-297. PubMed ID: 36029366
[TBL] [Abstract][Full Text] [Related]
14. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
Front Immunol; 2020; 11():762. PubMed ID: 32457743
[TBL] [Abstract][Full Text] [Related]
15. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
16. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
17. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
18. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
Caraccio C; Krishna S; Phillips DJ; Schürch CM
Front Immunol; 2020; 11():501. PubMed ID: 32391000
[TBL] [Abstract][Full Text] [Related]
20. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]